Comparison of therapeutic responses to an anticancer drug in three stocks of ICR mice derived from three different sources

Abstract

Korl:ICR mice, established by the Korean National Institute of Food and Drug Safety Evaluation (NIFDS), are characterized based on their genetic variation, response to gastric injury, and response to constipation inducers. To compare the inhibitory responses of ICR stocks obtained from three different sources to the anticancer drug cisplatin (Cis), alterations in tumor volume, histopathological structure, and toxicity were examined in Sarcoma 180 tumor-bearing Korl:ICR, A:ICR (USA source), and B:ICR (Japan source) mice treated with low and high concentrations of Cis (L-Cis and H-Cis, respectively). Tumor size and volume were lower in H-Cis-treated mice than in L-Cis-treated mice in all three ICR stocks with no significant differences among stocks. There was a significant enhancement of the necrotizing areas in the histological structures in the L-Cis- and H-Cis-treated groups relative to that in the untreated group. The necrotizing area changes were similar in the Sarcoma 180 tumor-bearing Korl:ICR, A:ICR, and B:ICR mice. However, there were stock-bases differences in the serum biomarkers for liver and kidney toxic effects. In particular, the levels of AST, ALT and BUN increased differently in the three H-Cis-treated ICR stocks, whereas the levels of ALP and CRE were constant. Taken together, the results of the present study indicate that Korl:ICR, A:ICR, and B:ICR mice have similar overall inhibitory responses following Cis treatment of Sarcoma 180-derived solid tumors, although there were some differences in the magnitude of the toxic effects in the three ICR stocks.

Comparison of intrinsic exercise capacity and response to acute exercise in ICR (Institute of Cancer Research) mice derived from three different lineages

“…To further validate our aforementioned results, we investigated the difference in the magnitude of response to acute exercise. Consistent with our recent observations and those of other studies involving the same ICR lineages [ 3 , 5 – 7 ], the results revealed a higher level of LDH in B:ICR mice than in Korl:ICR mice, accompanied with a sharp decline in the blood glucose level coupled with an increase in exercise intensity. However, we did not observe significant mouse lineage-dependent differences with respect to biological properties (e.g., body weight and muscle tissue mass) and the level of corticosterone and MDA, although they showed a tendency to increase linearly with increase in exercise intensity.…”

“…Among the diverse lineages of rodents supplied by major vendors of laboratory animals, the ICR mouse, developed in 1945 at the Institute of Cancer Research (ICR), is commonly used in the research field of genetics, neurobiology, immunology, and pharmacology (drug efficacy and safety). This has led to the development of several lineages of ICR mouse worldwide for various research purposes [ 1 – 3 ].…”

“…Korl:ICR, a novel mouse lineage recently developed in the ICR strain background by the National Institute of Food and Drug Safety Evaluation (NIFDS) in Korea, has been rotation-mated for over 19 generations and is currently under genetic and phenotypic verification [ 4 , 5 ]. Recently, our research groups found that, with the exception of certain phenotypic characteristics, the responses of Korl:ICR mice to diverse chemicals and physiological stimulations (e.g., gastric injury, constipation inducer, and anticancer drug treatment) are similar to those of two other lineages of different origins (the United States and Japan) supplied by commercial vendors [ 3 , 5 – 7 ].…”

Irinotecan (CPT-11) Treatment Induces Mild Gonadotoxicity

“…ICR mice are one of the most popular strains of outbred mice used in in pharmacology and oncology studies. This strain have been used extensively in toxicology and pharmacology studies and is often used for product safety testing (21)(22)(23)(24)(25)(26). Animal care and all experiments were in accordance with institutional guidelines and were approved by the Institutional Animal Care and Use Committee, Sackler Faculty of Medicine, Tel-Aviv University, ID TAU-R 100106.…”